Young Jonathan — SEC Form 4 filings
SEC reporting owner CIK 1779805. 30 Form 4 filings on record with FilingPulse; latest filed 2025-12-09.
Transaction summary — filings shown
Covers all 30 filings on record, filed 2024-03-05 to 2025-12-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 35 legs across 24 filings — 259,593 shares, $9,379,905 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 41.
- Largest priced transaction: sale of 38,553 shares @ $45.07 ($1,737,622) in Akero Therapeutics, Inc., filed 2025-03-05.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Akero Therapeutics, Inc. (AKRO) | Chief Operating Officer | 30 | — | 35 legs · 259,593 sh · $9,379,905 | 41 |
Form 4 filings — Young Jonathan
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2025-12-09 | 4 | Akero Therapeutics, Inc. (AKRO) | Disposition to issuer (D): 152,616 · Disposition to issuer (D): 20,000 · Disposition to issuer (D): 20,000 · Disposition to issuer (D): 20,000 · Disposition to issuer (D): 47,573 · Disposition to issuer (D): 3,421 (derivative) · +10 more | EDGAR |
| 2025-11-26 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 4,284 @ $21.09 · Option exercise (M): 3,527 @ $28.35 · Option exercise (M): 4,739 @ $21.10 · Gift (G): 9,259 @ $0 · Option exercise (M): 4,284 (derivative) @ $0 · Option exercise (M): 3,527 (derivative) @ $0 · +1 more | EDGAR |
| 2025-10-03 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 12,500 @ $21.10 · Sale (S): 8,299 @ $47.64 · Sale (S): 4,201 @ $47.98 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 586 @ $43.02 | EDGAR |
| 2025-09-04 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 12,500 @ $21.10 · Sale (S): 9,700 @ $45.78 · Sale (S): 2,739 @ $47.14 · Sale (S): 61 @ $47.58 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2025-08-13 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 12,500 @ $21.10 · Sale (S): 11,151 @ $47.72 · Sale (S): 1,349 @ $48.32 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 890 @ $23.87 | EDGAR |
| 2025-06-20 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 1,453 @ $54.84 | EDGAR |
| 2025-06-12 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 2,493 @ $53.99 | EDGAR |
| 2025-03-14 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 607 @ $44.88 | EDGAR |
| 2025-03-05 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 11,447 @ $44.17 · Sale (S): 38,553 @ $45.07 | EDGAR |
| 2025-02-05 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 5,100 @ $53.56 · Sale (S): 4,900 @ $54.06 | EDGAR |
| 2025-01-27 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 43,064 @ $6.36 · Option exercise (M): 43,064 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 10,000 @ $28.03 | EDGAR |
| 2024-12-18 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 24,300 @ $0 · Grant/award (A): 73,700 (derivative) @ $0 | EDGAR |
| 2024-12-12 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 2,503 @ $30.79 | EDGAR |
| 2024-12-04 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 10,000 @ $32.13 | EDGAR |
| 2024-11-05 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 40,716 @ $21.09 · Sale (S): 34,943 @ $31.25 · Sale (S): 15,481 @ $32.27 · Sale (S): 292 @ $32.94 · Option exercise (M): 40,716 (derivative) @ $0 | EDGAR |
| 2024-10-16 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 40,000 @ $21.09 · Sale (S): 40,000 @ $30.15 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2024-10-03 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 10,000 @ $28.18 | EDGAR |
| 2024-09-13 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 568 @ $26.18 | EDGAR |
| 2024-09-05 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 3,710 @ $26.42 · Sale (S): 1,290 @ $27.58 | EDGAR |
| 2024-08-02 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 3,031 @ $26.44 · Sale (S): 1,969 @ $27.23 | EDGAR |
| 2024-07-02 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 1,064 @ $19.94 · Sale (S): 5,000 @ $23.40 | EDGAR |
| 2024-06-13 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 2,516 @ $22.64 | EDGAR |
| 2024-06-05 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 5,000 @ $19.29 | EDGAR |
| 2024-05-02 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 5,000 @ $20.15 | EDGAR |
| 2024-04-03 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 4,600 @ $24.33 · Sale (S): 400 @ $25.02 | EDGAR |
| 2024-03-15 | 4 | Akero Therapeutics, Inc. (AKRO) | Sale (S): 651 @ $28.33 | EDGAR |
| 2024-03-05 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 83,321 @ $0.61 · Option exercise (M): 83,321 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1779805 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →